Autres langues Johnson & Johnson

Actions

JNJ

US4781601046

Temps réel estimé Cboe BZX Autres places de cotation 17:47:14 30/05/2024			Varia. 5j.	Varia. 1 janv.
145,2 ^USD	+0,54 %		-3,17 %	-7,52 %

10:58	Sarepta Therapeutics va remplacer Shockwave Medical dans le S&P MidCap 400	MT
29/05	Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	10:58
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	29/05
J&J : résultats encourageants dans le soin de la dépression	29/05
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	29/05
J&J's treatment for depression succeeds in late stage study	29/05
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05
Sector Update: Health Care Stocks Fall Late Afternoon	28/05
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	28/05
Sector Update: Health Care	28/05
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK	28/05
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	28/05
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	28/05
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	28/05
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	28/05
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	28/05
J&J : rachat d'une biotech suisse dans l'eczéma	28/05
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal	28/05
J&J acquires rights to skin disorder drug for $1.25 bln	28/05
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	28/05
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	28/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30